Amarin Corp Plc (AMRN)

[Biobillionair]

I do believe you are correct....and this is why MAPP 5021 was instrumental in the approval of NCE for Vascepa as it excluded Ethyl Esters. The Lovaza CP manipulated the MAPP 5021 angle and snuck the CP in two weeks before being posted and active. It was almost like the CP filer new about MAPP 5021...but that couldn't be the case;)

John Fuson Author of Lovaza CP and Ex FDA Attorney, last date of FDA employment May 2012.

John likely happened to work on the draft of 5021 when employed at the FDA 10 short months prior...I bet numerous FDA documents could support that statement.

http://www.linkedin.com/profile/view?id=39380015&authType=NAME_SEARCH&authToken=1sKk&locale=en_US&srchid=2121059301376651147378&srchindex=1&srchtotal=3&trk=vsrp_people_res_name&trkInfo=VSRPsearchId%3A2121059301376651147378%2CVSRPtargetId%3A39380015%2CVSRPcmpt%3Aprimary&_mSplash=1

If GSK hired Mr. Fuson and then responded to their own CP we're looking at violations that dawf their China issues.